Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 88

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 88
---
Item 4. Information on the Company.

A. History and Development of the Company

Innate's legal name and commercial name is Innate Pharma S. A. The Company was incorporated under the laws of France on September 23, 1999, as a société par actions simplifiée and converted into a société anonyme, or S. A., on June 13, 2005. Innate's headquarters are located at 117, Avenue de Luminy, 13009 Marseille, France. In 2008, The Company incorporated its wholly owned U. S. subsidiary, Innate Pharma Inc. In 2019, Innate Pharma's incorporated its wholly owned French subsidiary, Innate Pharma France S. A. S. (registered under number SIREN 844 853 119). Innate Pharma France S. A. S. was dissolved without liquidation on November 30, 2020, under article 1844-5, Section 3 of the French Civil Code.

The Company is registered at the Marseille Business and Company Registry (Registre du commerce et des sociétés) under the number SIREN 424 365 336 RCS Marseille. Innate's telephone number at its principal executive offices is +33 4 30 30 30 30. Innate Pharma's wholly owned U. S. subsidiary is located at 2273 Research Boulevard, Suite 350, Rockville, MD 20850, United States.

Innate's website address is www. innate-pharma. com. The reference to its website is an inactive textual reference only, and information contained in, or that can be accessed through, its website is not part of this Annual Report. The SEC maintains a website (www. sec. gov) that contains reports, proxy and information statements and other information regarding registrants, such as Innate, that file electronically with the SEC.

Innate's capital expenditures in the years ended December 31, 2022, and

B. Business Overview

Innate Pharma S. A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET®(A ntibody-based NK cellE ngagerT herapeutics) proprietary platform. Innate’s portfolio includes our lead proprietary program lacutamab, developed for advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas